Armata Pharmaceuticals Achieves Full Enrollment for Study on Potential Treatment for Staphylococcus Aureus Bacteremia

Armata Pharmaceuticals has recently announced that it has completed the enrollment for its Phase 1b/2a diSArm study, evaluating intravenous AP-SA02 as a possible treatment for Staphylococcus aureus bacteremia. The company stated that this achievement signifies a significant step in the development of AP-SA02, bringing them closer to introducing a new treatment option for patients afflicted with this serious bloodstream infection.

In a press release issued on November 12, 2024, Armata Pharmaceuticals highlighted that the full enrollment of the diSArm study, with a total of 50 participants, has paved the way for the anticipation of topline data expected in the first quarter of 2025. Dr. Deborah Birx, the Chief Executive Officer of Armata, expressed optimism about the progress made with the study and the potential positive outcomes that could lead to the initiation of a pivotal bacteremia efficacy trial later in 2025.

During the Phase 2a segment of the diSArm study, Armata focused on assessing the safety of higher intravenous doses of AP-SA02 and expedited enrollment to swiftly reach topline data. Notably, the company’s proprietary methods enabled the escalation of doses to 5E10 PFU every six hours for five days without significant adverse effects. Additionally, observations on two distinct subsets of subjects receiving phage indicated early evidence of in vivo phage amplification, with topline data expected to shed further light on these subsets.

The Company remains dedicated to advancing a pivotal S. aureus bacteremia trial in 2025 to evaluate the potential of AP-SA02 as a complementary treatment to standard broad-spectrum antibiotics or as a possible alternative. The clinical development of AP-SA02 is supported, in part, by funds from the Defense Health Agency and Joint Warfighter Medical Research Program, managed by the NMRC-NAMD through the MTEC.

The diSArm study, a randomized, double-blind, placebo-controlled multiple ascending dose escalation study, focuses on evaluating the safety, tolerability, and efficacy of intravenous AP-SA02 for the treatment of adults with S. aureus bacteremia. The Phase 1b part assessed safety and tolerability, while the Phase 2a segment concentrated on efficacy, safety, and tolerability of multiple doses of intravenous AP-SA02.

Armata Pharmaceuticals is a clinical-stage biotechnology company specializing in pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections. The company’s commitment to advancing phage therapy underscores its efforts to introduce innovative treatment solutions for challenging infections.

Investors and stakeholders eagerly await the topline data from the diSArm study, anticipating potential advancements in the field of bacteriophage therapeutics and the treatment of Staphylococcus aureus bacteremia.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Ampliphi Biosciences’s 8K filing here.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.